Navigation Links
Key protein molecule linked to diverse human chronic inflammatory diseases
Date:9/15/2008

Blacksburg, Va. -- Liwu Li, associate professor of biological sciences at Virginia Tech, has revealed a common connection between the cellular innate immunity network and human chronic inflammatory diseases, including atherosclerosis, Type 2 Diabetes, and neurodegenerative diseases. The finding presents a viable cellular and molecular target for the diagnosis and treatment of serious human inflammatory diseases, according to Li.

"Researchers and physicians have long recognized that there is an association between these conditions. For example, obesity increases the risk of heart attack or stroke, Type 2 Diabetes or insulin resistance, and Alzheimer's Disease," said Li, who is the founding director of the Inflammation Center at Virginia Tech.

"Inflammation is the common mechanism," he said. "Inflammation is a double-edged sword. Proper inflammation is necessary to fend off infection and abnormal cell growth. On the other hand, excessive inflammation contributes to diverse chronic diseases, including atherosclerosis, diabetes, and lupus." However, the complex cellular and molecular networks controlling inflammation are still poorly understood, he said. "The lack of understanding impedes our progress in treating serious chronic inflammatory diseases."

In a series of studies published throughout the last decade*, Li's group has defined several critical signaling networks essential for the modulation of inflammation. In particular, a key cellular protein kinase named interlukin-1 receptor associated kinase 1 (IRAK-1) was shown to be critical for processing diverse inflammatory signals, including microbial products, cytokines, and insulin. Li's group discovered that excessive IRAK-1 activation is linked with the risk of atherosclerosis and diabetes. Using transgenic mice without the IRAK-1 gene, Li's group demonstrated that IRAK-1 deficient mice are protected from developing atherosclerosis and insulin resistance.

At the molecular level, Li's laboratory discovered that IRAK-1 prefers to phosphorylate transcription factors harboring the Serine-Proline motif including STAT-3 and NFAT. Subsequently, STAT-3 and NFAT are involved in modulating the expression of distinct inflammatory mediators responsible for the excessive activation of specialized macrophages and T cells. These cells eventually contribute to diverse inflammatory symptoms including cardiovascular diseases, diabetes, Alzheimer's diseases, and lupus. "Chemical compounds targeting this molecule will have enormous therapeutic potential," Li said.

"There is still a long way to go for finding the actual cure for these diseases," he said. "That is why we are combining expertise from various disciplines, including experimental biology and computational simulation. The Inflammation Center integrates faculties with expertise in experimental molecular biology, cutting edge imaging of inflamed cells and tissues, computational simulation of cellular signaling networks, human and animal studies, and nano-technologies designing novel intervention."

Virginia Tech Intellectual Properties Inc. (VTIP) filed a patent application for Li's discovery and its use as a diagnostic tool and treatment strategy. "This technology will still take some time before there is a product," said Li.


'/>"/>

Contact: Susan Trulove
STrulove@vt.edu
540-231-5646
Virginia Tech
Source:Eurekalert

Related medicine news :

1. Protein switch suppresses skin cancer development
2. Scientists Track Hourly Changes in Alzheimers Protein
3. Computer-Based Method IDs Alzheimers Protein Structures
4. Bone Growth Protein Also Promotes Good Fat
5. Fat Cell Protein Boosts Heart Attack Risk in Elderly
6. Protein Key to Brain Rewiring
7. Recipe for cell reprogramming adds protein
8. Key to virulence protein entry into host cells discovered
9. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
10. Protein made by fat cells may increase risk of heart attack in older adults
11. Scientists ID Jekyll-Hyde Protein in Lou Gehrigs Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as ... that Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual ... that was started in 2003 to salute young achievers in Southwest Florida who have ...
(Date:9/21/2017)... ... ... SABRE is raising awareness about personal safety with a Chicago Transit Authority ... The Chicago, Illinois, based self-defense brand has been waiting for an opportunity like this ... their personal safety into their own hands. , The ads focus on their diverse ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up with ... In the competitive world of drug and device marketing and promotion, drug and ... rules. , The FDA has issued two draft guidances that are the closest ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... or exercise more try taking a more holistic approach and use natural alternatives ... Amazon essential oil collection is certified USDA guaranteeing that, the new line of ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
Breaking Medicine Technology: